Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals

Table 3

The association between the ADRB3 rs4994 genotype and the risk of NAFLD in normal-weight and overweight/obese subjects.

Weight status	ADRB3 genotype	NAFLD		OR [95% CI]	value^†
		Absent	Present
Normal-weight	T/T	184 (94.8)	10 (5.2)	1
	T/C	92 (92.0)	8 (8.0)	1.92 [0.67–5.51]	0.18
	C/C	12 (100.0)	0 (0.0)	—	—
Overweight/obese	T/T	115 (66.9)	57 (33.1)	1
	T/C	65 (63.7)	37 (36.3)	1.29 [0.73–2.29]	0.39
	C/C	4 (36.4)	7 (63.6)	4.40 [1.08–17.93]	0.04
Overweight	T/T	107 (69.5)	47 (30.5)	1
	T/C	61 (68.5)	28 (31.5)	1.17 [0.63–2.19]	0.62
	C/C	3 (37.5)	5 (62.5)	6.18 [1.25–30.64]	0.03

ADRB3: beta-3-adrenergic receptor; NAFLD: nonalcoholic fatty liver disease; OR: odds ratio; CI: confidence interval. Data are the number (%). Adjusted by age, HOMA-IR, and dyslipidemia. ^†Analyzed using a logistic regression analysis.